VOLITIONRX LTDVNRXEarnings & Financial Report
VolitionRx Ltd is a global life sciences company focused on developing non-invasive blood-based diagnostic tests for early cancer detection via its proprietary nucleosomics platform. It serves clinical, research and biopharmaceutical partners primarily across North America and Europe, delivering accessible early disease screening solutions.
VNRX Q4 FY2025 Key Financial Metrics
Revenue
$447.0K
Gross Profit
N/A
Operating Profit
$-4.8M
Net Profit
$-6.3M
Gross Margin
N/A
Operating Margin
-1077.8%
Net Margin
-1402.8%
YoY Growth
133.2%
VOLITIONRX LTD Q4 FY2025 Financial Summary
VOLITIONRX LTD reported revenue of $447.0K (up 133.2% YoY) for Q4 FY2025, with a net profit of $-6.3M (down 8.2% YoY) (-1402.8% margin).
Key Financial Metrics
| Total Revenue | $447.0K |
|---|---|
| Net Profit | $-6.3M |
| Gross Margin | N/A |
| Operating Margin | -1077.8% |
| Report Period | Q4 FY2025 |
VOLITIONRX LTD Annual Revenue by Year
VOLITIONRX LTD annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.7M).
VOLITIONRX LTD Quarterly Revenue & Net Profit History
VOLITIONRX LTD results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $447.0K | +133.2% | $-6.3M | -1402.8% |
| Q3 FY2025 | $627.3K | +32.2% | $-5.4M | -857.4% |
| Q2 FY2025 | $406.7K | +2.8% | $-6.3M | -1545.2% |
| Q1 FY2025 | $246.4K | +43.6% | $-5.4M | -2201.3% |
| Q4 FY2024 | $191.7K | -21.4% | $-5.8M | -3022.8% |
| Q3 FY2024 | $474.5K | +187.2% | $-5.8M | -1226.8% |
| Q2 FY2024 | $395.8K | +83.0% | $-7.0M | -1764.9% |
| Q1 FY2024 | $171.5K | +14.5% | $-8.4M | -4877.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $171535 | $395797 | $474522 | $191657 | $246385 | $406688 | $627277 | $447034 |
| YoY Growth | 14.5% | 83.0% | 187.2% | -21.4% | 43.6% | 2.8% | 32.2% | 133.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $19.4M | $13.1M | $12.7M | $9.4M | $8.5M | $8.7M | $6.4M | $6.9M |
| Liabilities | $36.1M | $36.0M | $35.3M | $35.5M | $37.5M | $41.8M | $42.4M | $42.5M |
| Equity | $-15.6M | $-21.8M | $-21.5M | $-24.9M | $-27.8M | $-31.8M | $-34.6M | $-34.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.3M | $-6.7M | $-5.4M | $-5.4M | $-4.3M | $-6.3M | $-3.6M | $-5.5M |